



RELIEF THERAPEUTICS Holding AG announces its financial results for the half-year ended 30 June 2016.

(dates corrected from previous press release)

Zurich, Switzerland, 22 September 2016

RELIEF THERAPEUTICS Holding AG (“Relief”, “the Company”) published yesterday its consolidated financial results for the half-year ended 30 June 2016.

For the half-year ended 30 June 2016 the Company generated income, from both continuing and discontinued operations, of CHF 4 million and EBITDA of negative CHF 1.7 million.

By comparison, for the half-year ended 30 June 2015, the Company generated income, from both continuing and discontinued operations, of CHF 7.9 million and EBITDA of negative CHF 2.3 million.

Raghuram Selvaraju, Chairman of the Board of Directors, comments: “The half-year financial statements published yesterday reflect the final chapter of the Company’s history in the CRO business. Moving forward as a purely drug development company, with a lean operating structure and a pipeline of promising drug candidates, Relief is now finally positioned to generate the return on investment its shareholders expect and deserve.”

(The financial period reported here has been corrected from the previous press release although the numbers reported remain the same.)

Click [here](#) to view the half-year financial statements.

About Relief Therapeutics Holding AG

RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck-Serono, a division of the global established pharmaceutical firm Merck KGaA, and has been the subject of multiple clinical trials and over €100 million in total capital investment. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach \$4.1 billion in 2019, according to Datamonitor. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.

For further information, please visit the Relief website at www.relieftherapeutics.com or contact investor relations at:

Relief Therapeutics Holding AG

Investor Relations

Dr. Raghuram Selvaraju

Tel: +41 44 723 59 59

investors@relieftherapeutics.com



Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding AG is providing this communication as of this date and does not undertake to update any forward looking statements contained herein as a result of new information, future events or otherwise